A Phase 2/3 interventional study of Prednisone and Vinblastine in Langerhans Cell Histiocytosis, sponsored by North American Consortium for Histiocytosis. Active, not recruiting at 42 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by North American Consortium for Histiocytosis · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States — 8 open to participants now, 25 under way, 2 of them phase 3. Histiocytosis, Langerhans-Cell · United States.
Among the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, this one has the largest enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2016, is one of 2 in phase 2/3, reaches primary completion later than 23 of the 24 other live ones, and was the 17th registered.
81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.
Browse Histiocytosis, Langerhans-Cell studies →8 of the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Cook Children's Health Care System · Sites in United States
Ages 1–30
National Cancer Institute (NCI) · Sites in United States, Australia, Canada
Ages 180 days–22 yrs
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 2+
University of Alabama at Birmingham · Sites in United States
Ages 0–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 32 · Phase 3 3 · Phase 4 1
First in 1995; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,400 is above the median of 24 across 64 interventional studies indexed under Histiocytosis, Langerhans-Cell.
Median enrollment 21 across the 40 interventional studies, 297 across the 6 observational. Of the 21 that completed or were terminated, 13 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 47 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with North American Consortium for Histiocytosis as lead sponsor.
North American Consortium for Histiocytosis has 1 study filed under Histiocytosis, Langerhans-Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Histiocytosis, Langerhans-Cell with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02670707Phase 3Baylor College of MedicineVinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) | 2027-01 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT05915208University of Alabama at BirminghamHistiocytic Disorder Follow-up Study | 2027-07 |
| NCT03329274Memorial Sloan Kettering Cancer CenterRegistry for Patients With Erdheim-Chester Disease and Other Histiocytoses | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
The international efforts of the past 20 years have shown that combination therapy with vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients with and without risk organ involvement. It also showed that prolonged treatment in the latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV study seeks to tailor treatment based on features at presentation and on response to treatment, leading to seven strata:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stratum I
Stratum II
Stratum III
Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as
Stratum IV
Stratum V
Stratum VI
-- Patients with newly diagnosed SS-LCH and localization other than "multifocal bone",isolated tumorous CNS lesion, or isolated "CNS-risk" lesion.
Exclusion Criteria:
Stratum I
Stratum II
Stratum III
Stratum IV
Stratum VI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV). Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences.
Drug: Prednisone · Drug: Vinblastine · Drug: mercaptopurine
A uniform "intensive" 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms "INDOMETHACIN" and "6-MP/MTX" (mercaptopurine and Methotrexate).
Drug: Prednisone · Drug: Vinblastine · Drug: mercaptopurine · Drug: INDOMETHACIN · Drug: Methotrexate · Drug: Cytosine Arabinoside
Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy. The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum.
Drug: 2-chlorodeoxyadenosine
To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).
Procedure: hematopoietic stem cell transplantation (RIC-HSCT)
Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH \- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice.
Drug: Cytosine Arabinoside · Drug: 2-chlorodeoxyadenosine · Biological: Intravenous immunoglobulin
Natural history and management of "other" SS-LCH not eligible for stratum I group 2. * Treatment Options- Management (mostly "wait \& see" and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator. * Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy. * Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V.
Drug: Prednisone · Drug: Vinblastine · Drug: mercaptopurine · Drug: Cytosine Arabinoside · Drug: 2-chlorodeoxyadenosine · Biological: Intravenous immunoglobulin
Stratum I
Stratum I
Also known as: Velban®, Vincaleukoblastine Sulfate
Stratum I
Also known as: -Purinethol®, -6-MP
Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
fixed dose weekly orally for total treatment duration of 24 months.
Also known as: Cytarabine, Ara-C
Also known as: 2-CdA, Cladribin®, Leustatin®
Also known as: IVIG
Percentage of Patients with Reactivation Free Survival
Stratum I, II, VI
Time frame: 12 Months
Response Rate of Second Cycle
Stratum III
Time frame: 9 weeks
Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)
Stratum IV
Time frame: 3 Years
The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions
Stratum V
Time frame: 2 Years
The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH
Stratum V
Time frame: 2 Years
Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.
From all treatment stratum via long-term follow up in Stratum VII
Time frame: 2 Years
Overall Survival
Stratum I
Time frame: 2 Years
Number of Participants with Serious and Non-Serious Adverse Events
Time frame: 2 Years
Incidence of Permanent Consequences
All Stratum
Time frame: 2 Years
Cumulative incidence of reactivations in risk organs
Time frame: 2 Years
Time to complete disease resolution
Stratum III
Time frame: 2 Years
Response rate to the combination of prednisone, vincristine and cytarabine
Stratum II
Time frame: 2 years
The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)
Stratum II
Time frame: 2 Years
Percentage of treatment-related toxicities
Stratum II
Time frame: 2 Years
Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.
Stratum II
Time frame: 2 years
The type of subsequent intensive and/or maintenance therapy utilized
Stratum III
Time frame: 2 Years
Early and late mortality
Stratum II
Time frame: 2 Years
Early and late toxicity
Stratum III
Time frame: 2 Years
d+100 transplant related mortality
Stratum IV
Time frame: 2 Years
Incidence of hematopoietic recovery, and donor chimerism at d+100 and 1 year post RIC-HSCT
Time frame: 2 Years
Record all occurrence of skin, GI or liver abnormalities fulfilling criteria of Grades II-IV acute GVHD
Stratum IV: Hematopoetic Stem Cell Transplantation for Risk LCH
Time frame: 2 Years
Percentage of Participants with incidence of chronic GVHD
Stratum IV
Time frame: 2 Years
Response Rate to ND-CNS-targeted therapy at 12 and 24 months after start of therapy
Stratum V
Time frame: 2 years
Response of isolated tumorous CNS-LCH to 2-CDA
Stratum V
Time frame: 2 Years
Frequency of ND-CNS-LCH in patients with isolated tumorous CNS-LCH
Stratum V
Time frame: 2 Years
Methods of early identification of ND-CNS-LCH
Stratum V - Exploration of the value of neurochemistry, neurophysiology, and neuropsychology methods in early identification of ND-CNS-LCH and in assessing its severity, and comparison to MRI findings.
Time frame: 2 Years
Need for systemic therapy later during disease course
Stratum VI
Time frame: 2 Years
Identify possible risk factors for permanent consequences (PC)
Time frame: 2 Years
The record gives a start of Nov 2016, a primary completion of Nov 2031 and a completion of Nov 2031. It does not say whether these dates are actual or estimated.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2026 → Nov 2031 and completion Jul 2026 → Nov 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Prednisone · Vinblastine · Mercaptopurine · Indomethacin · Methotrexate · Cytarabine · Cladribine · Immunoglobulins, Intravenous
Histiocytosis, Langerhans-Cell →